Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
OSM
REST API REST API
Homo sapiens
OSM is differentially expressed in 121 experiments: 33 organism parts: bone marrow, lung, ... (31 more);, 45 disease states: normal, septic shock, ... (43 more);, 43 cell types 73 cell lines 21 compound treatments and 43 other conditions.
Synonyms MGC20461
Orthologs Osm (Mus musculus)   OSM (Bos taurus)   Osm (Rattus norvegicus)   OSM (Canis familiaris)   (Compare orthologs)
Gene Ontology Term positive regulation of cell division, apoptosis, cell proliferation, negative regulation of cell proliferation, extracellular space, positive regulation of cell proliferation, growth factor activity, extracellular region, cytokine activity, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, immune response, response to heat, regulation of growth, peripheral nervous system development, positive regulation of peptidyl-serine phosphorylation, tyrosine phosphorylation of Stat5 protein, positive regulation of peptidyl-tyrosine phosphorylation, negative regulation of meiosis, negative regulation of hormone secretion, oncostatin-M receptor binding, tyrosine phosphorylation of Stat1 protein, oncostatin-M receptor complex, positive regulation of acute inflammatory response, positive regulation of MAPKKK cascade, behavioral response to pain, tyrosine phosphorylation of Stat3 protein
InterPro Term Leukemia_IF/oncostatin
UniProt Accession P13725, B5BUQ7, B5MC70, B5MCX1
Search EB-eye ENSG00000099985
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-1563, E-GEOD-6919, E-TABM-130, E-GEOD-1402, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-MTAB-37, E-GEOD-12662, E-GEOD-19639, E-GEOD-24147, ... (9 experiments)

Factor Value U/D Experiments
Daudi
1
E-MTAB-37
HepG2
1
E-GEOD-21154
JAR
1
E-MTAB-37
NALM1
1
E-MTAB-37
NCIH187
1
E-MTAB-37
HDMYZ
1
E-MTAB-37
67 more value(s).


Cell type

studied in E-GEOD-18811, E-GEOD-22529, E-GEOD-19069, E-GEOD-22373, E-TABM-130, ... (20 experiments)

Factor Value U/D Experiments
activated natural killer cell (supplemented for IL2 for 24 hours)
1
E-TABM-702
liver cancer
1
E-GEOD-21154
naive T cell
1
E-GEOD-1460
spermatid
1
E-TABM-130
vascular smooth muscle cell
1
E-TABM-130
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
37 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-19743, E-GEOD-6872, E-GEOD-22529, E-GEOD-15960, ... (20 experiments)

Factor Value U/D Experiments
lymphoma
1
E-MTAB-37
gastric carcinoma
1
E-GEOD-2685
B cell chronic lymphocytic leukemia
1
E-GEOD-13987
ovarian carcinoma
1
E-MTAB-37
adenoma
1
E-GEOD-15960
testicular seminoma
1
E-GEOD-8607
39 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-412, E-GEOD-4984, E-GEOD-2803, E-GEOD-15811, ... (12 experiments)

Factor Value U/D Experiments
none
5
E-GEOD-412, E-MEXP-1958, E-GEOD-2803, E-GEOD-2649, E-GEOD-5099 ... (5 experiments)
sevoflurane
1
E-GEOD-4386
ethanol
1
E-MEXP-2241
BCR/ABL1
1
E-GEOD-15811
S-nitrosoglutathione plus dibutyryl cAMP
1
E-GEOD-2649
bacterial endotoxin
1
E-GEOD-3284
15 more value(s).


Biosource provider

studied in E-MTAB-37

Factor Value U/D Experiments
ECACC
1
E-MTAB-37
DSMZ
1
E-MTAB-37


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-512 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-4619, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-2666

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7011, E-GEOD-7578, E-MTAB-108

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-MEXP-1403

Growth condition
studied in E-GEOD-20540, E-GEOD-9764, E-MEXP-2146, E-GEOD-20505

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-1290, E-MEXP-2069, E-GEOD-1926, ... (16 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-MEXP-1403

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254

Replicate
studied in E-GEOD-10896

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-23984

stimulus
studied in E-GEOD-22103

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198 ... (5 experiments)

Processing time: 0.348 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM